glp·helper
glphelper.com/ozempic/arizona
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Arizona

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Ozempic is FDA-approved for type 2 diabetes, not for weight management.[1] The semaglutide approved for chronic weight management is Wegovy in Arizona.

Physicians across Arizona from the federal NPI registry. Ask each office whether it prescribes Ozempic.[9]

state providers
769
as of today
Get matched with a provider →Tell us your state and insurance. We’ll match you with a licensed Ozempic provider.

Same molecule (semaglutide): Wegovy in Arizona, Semaglutide in Arizona

Other GLP-1 medicines: Tirzepatide in Arizona, Mounjaro in Arizona, Zepbound in Arizona

§ 02Provider directory: Arizona
24 of 769 shown

Find an Ozempic provider in Arizona.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone

The list above samples the largest towns. Each town page below lists every physician there, 769 across Arizona.

Ozempic by Arizona town, physicians per town
§ 03Getting Ozempic in Arizona
769 providers · 32 metros

How a prescription works in Arizona.

You don’t have to leave Arizona to start. Because semaglutide isn't a controlled substance, a Arizona-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 769 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in Arizona
Ozempic (semaglutide) is a GLP-1, not a controlled substance, so a Arizona-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
AZ-licensed clinicians
Any physician, nurse practitioner, or PA licensed in Arizona can prescribe Ozempic. The 769 providers below are checked against the NPI registry and the Arizona board.
Medicaid (weight loss)
Diabetes only
As of April 2026, Arizona Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Arizona’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In the trials on its FDA label, the 1 mg dose lowered HbA1c by 1.4 to 1.9 percentage points and body weight by a mean of 4.7 to 6.0 kg over 30 to 56 weeks. The 2 mg dose lowered body weight by a mean of 6.4 kg over 40 weeks.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

Bar chart of Ozempic dose strengths on the FDA label: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Ozempic comes in 4 strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceNDC 0169-4132
Active ingredient
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Wegovy is the semaglutide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy
§ 05Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.9%
mean, 1 mg dose, 30 to 56 wk[1]
Weight change
−4.7 to −6.0 kg
mean, 1 mg dose, 30 to 56 wk[1]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 06Safety & adverse events
from FDA label, sect. 6.1

Most Ozempic side effects are stomach and gut effects.

In Ozempic's diabetes trials at 0.5 mg and 1 mg, the most common side effects were nausea (15.8 to 20.3%), diarrhea (8.5 to 8.8%), and vomiting (5 to 9.2%). Most reports came during dose escalation.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15.8 to 20.3%
mild
Most common. Most reports came during dose escalation
Diarrhea
8.5 to 8.8%
mild
More frequent during dose escalation
Vomiting
5 to 9.2%
mild
Reduced by slower titration
Constipation
3.1 to 5%
mild
Abdominal pain
5.7 to 7.3%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 07Cost & coverage, published, not gated
USD · monthly

What Ozempic costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Ozempic monthly cost by how you pay
Pharmacy retail (no insurance)$1,476per monthBrand-name retail average, May 2026[6]
NovoCare self-pay, pen$349 to $499per month0.25, 0.5, and 1 mg $349. 2 mg $499
Commercial insurance (covered)$25 to $250per month copayVaries by PBM; T2D indication usually covered
Weight managementNot approvedOzempic is not FDA-approved for weight management. Wegovy is.
Medicare Part D$0 to $100per monthT2D covered; weight loss not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial only; eligibility limits apply
Find Ozempic providers in Arizona

Physicians from the federal NPI registry. Ask each office whether it prescribes Ozempic.

Ozempic in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Ozempic.

Related GLP-1 research
§ 08Frequently asked: Ozempic in Arizona

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Ozempic is a prescription-only medicine, marked Rx only on its label. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription.[1]